Phibro Animal Health (PAHC) Proxy filing summary

Executive summary

• Annual Meeting scheduled for November 3, 2026, to elect three Class I Directors and ratify the selection of PwC as independent auditor for FY 2027.

• Net sales for FY 2026 reached $1.5 billion, with adjusted EBITDA up 39% to $255 million and net income up $51.5 million to $99.7 million.

• Animal Health segment net sales grew 21%, with notable gains in medicated feed additives, nutritional specialties, and vaccines.

• Board recommends voting for all director nominees and auditor ratification.

Voting matters and shareholder proposals

• Shareholders will vote on electing three Class I Directors (Daniel M. Bendheim, Jonathan Bendheim, Sam Gejdenson) for terms expiring in 2029.

• Proposal to ratify PwC as independent registered public accounting firm for FY ending June 30, 2027.

• Shareholders may submit proposals for the 2027 meeting by May 24, 2027, and must follow advance notice procedures for other business.

Board of directors and corporate governance

• Board consists of eight members divided into three staggered classes; majority are independent under Nasdaq rules.

• BFI controls a majority of voting power, qualifying the company as a "controlled company" under Nasdaq standards, exempting it from certain governance requirements.

• Two standing committees: Audit (all independent) and Compensation (all independent), with written charters and regular meetings.

• Recent leadership transition: Jack C. Bendheim became Executive Chairman; Daniel M. Bendheim appointed President and CEO effective July 1, 2026.